Retrospective clinical study of adjuvant electro-hyperthermia   treatment for advanced brain-gliomas

Hüseyin Sahinbas; Dietrich H. W. Grönemeyer; Eckhard Böcher; Andras Szasz

doi:10.1055/s-2007-986020

Deutsche Zeitschrift für Onkologie, Inhaltsverzeichnis

Deutsche Zeitschrift für Onkologie 2007; 39(4): 154-160
DOI: 10.1055/s-2007-986020

Forschung

Retrospective clinical study of adjuvant electro-hyperthermia treatment for advanced brain-gliomas

Hüseyin Sahinbas¹ , Dietrich H. W. Grönemeyer¹ , Eckhard Böcher² , Andras Szasz³

¹University Witten-Herdecke, Institute of Microtherapy, Universitätstrasse 142, 44799-Bochum, Germany;
²Clinic „Closter Paradise”, Im Stiftsfeld 1, 59494-Soest, Germany;
³St. Istvan University, Biotechnics Department, Szent Istvan krt. 20., 1137-Budapest, Hungary

Abstract

Summary

Malignant gliomas represent about 70 % of all brain tumors. Despite advances in standard therapy consisting of surgery, radiation therapy and chemotherapy, gliomas remain an essentially fatal disease, with a median survival time of 10 to 12 months and a 2-year survival rate of 8 % to 12 %. Electro-hyperthermia applied either alone or in combination with chemo- and/or radio-therapy is an advanced hyperthermia technique that has been used as adjuvant treatment for patients with malignant glioma. We present the results of a retrospective study of 140 patients with different stages of malignant glioma, which were treated/followed from January 2000 to February 2005. The endpoint was the overall survival and the survival from the 1st electro-hyperthermia treatment. The overall median survival time for patients with mostly advanced malignant glioma who received adjuvant electro-hyperthermia in this study was 20.4 months. The median survival time from the first electro-hyperthermia treatment was 6.6 months. Electro-hyperthermia was safe and well tolerated. The presented results show the feasibility of the treatment and suggest a benefit of the electro-hyperthermia treatment for patients with advanced malignant glioma.

Keywords

Malignant glioma - hyperthermia - chemotherapy - radiotherapy - survival rates

Volltext

Referenzen

References

01 Begley D J. ABC transporters and the blood-brain barrier. Current pharmaceutical design. 2004; 10 1295-1312
02 Borok T L, Winter A, Laing J. et al . Microwave hyperthermia radiosensitized iridium-192 for recurrent brain malignancy. Med Dosim. 1988; 13 29-36
03 Davis D L, Ahlbom A, Hoel D, Percy C. Is brain cancer mortality increasing in industrial countries?. American Journal of Industrial Medicine. 1991; 19 421-431
04 Eikesdal H P, Bjorkhaug S T, Dahl O. Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma: lack of interaction with the angiogenesis inhibitor batimastat. Int J Hyperthermia. 2002; 18 141-152
05 Fan M, Ascher P W, Schrottner O. et al . Interstitial 1.06 Nd:YAG laser thermotherapy for brain tumors under real-time monitoring of MRI: experimental study and phase I clinical trial. Journal of Clinical Laser Medicine & Surgery.. 1992; 10 355-361
06 Fisher P G, Buffler P A. Malignant gliomas in 2005: where to GO from here?. JAMA. 2005; 293 615-617
07 Friedlander D R, Zagzag D, Shiff B. et al . Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. Cancer Research. 1996; 56 1939-1947
08 Greig N H, Ries L G, Yancik R, SRapoport S I. Increasing annual incidence of primary malignant brain tumors in the elderly. Journal of the National Cancer Institute.. 1990; 82 1621-1624
09 Guthkelch A N, Carter L P, Cassady J R. et al . Treatment of malignant brain tumors with focused ultrasound hyperthermia and radiation: results of a phase I trial. Journal of Neuro-oncology. 1991; 10 271-284
10 Hager D, Dziambor H, App E M. et al . The treatment of patients with high-grade malignant gliomas with RF-hyperthermia. Proc Am Soc Clin Oncol. 22 2003
11 Hermisson M, Weller M. Hyperthermia enhanced chemosensitivity of human malignant glioma cells. Anticancer Research. 2000; 20 1819-1823
12 Jendrossek V, Belka C, Bamberg M. Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opinion on Investigational Drugs. 2003; 12 1899-1924
13 Kahn T, Harth T, Bettag M. et al . Preliminary experience with the application of gadolinium-DTPA before MR imaging-guided laser-induced interstitial thermotherapy of brain tumors. J Magn Reson Imaging. 1997; 7 226-229
14 Kuratsu J, Ushio Y. Epidemiological study of primary intracranial tumours in elderly people. Journal of Neurology, Neurosurgery, and Psychiatry. 1997; 63 116-118
15 Kurzen H, Schmitt S, Naher H, Mohler T. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anti-cancer Drugs. 2003; 14 515-522
16 Ley-Valle A. [Non invasive intracranial hyperthermia with Electric Capacitive Transference -ECT- Intratumoral and cerebral thermometry results]. Neurocirugia. 2003; 14 41-45
17 Moran C J, Marchosky J A, Wippold 2nd F J, DeFord J A, Fearnot N E. Conductive interstitial hyperthermia in the treatment of intracranial metastatic disease. Journal of Neuro-oncology. 1995; 26 53-63
18 Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica. 2005; 109 93-108
19 Pagani E, Falcinelli S, Pepponi R. et al . Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity. International Journal of Oncology. 2007; 30 443-451
20 Pontiggia P, Duppone Curto F, Rotella G. et al . Hyperthermia in the treatment of brain metastases from lung cancer. Experience on 17 cases. Anticancer Research. 1995; 15 597-601
21 Sahinbas H, Groenemeyer D H W, Boecher E. et al .Hyperthermia treatment of advanced relapsed glioma and astrocytoma (abstract). 9th ICHO 85 2004
22 Sakaguchi Y, Stephens L C, Makino M. et al . Apoptosis in tumors and normal tissues induced by whole body hyperthermia in rats. Cancer Research. 1995; 55 5459-5464
23 Selker R G, Eddy M S, Deutsch M, Arena V C, Burger P. On the development of an interstitial radiation protocol for a multicenter consortium. Experience with permanent low-dose rate and temporary high-dose rate 125I implants in failed and newly diagnosed glioblastoma patients: quality assurance methodology and a possible future adjuvant for therapeutic enhancement. Journal of Neuro-oncology. 1995; 26 141-155
24 Sharma H S. Hyperthermia induced brain oedema: current status and future perspectives. The Indian Journal of Medical Research. 2006; 123 629-652
25 Sneed P K, Stauffer P R, McDermott M W. et al . Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics. 1998; 40 287-295
26 Stupp R, Mason W P, Bent M J van den. et al . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine. 2005; 352 987-996
27 Sumiyoshi K, Strebel F R, Rowe R W, Bull J M. The effect of whole-body hyperthermia combined with ‚metronomic’ chemotherapy on rat mammary adenocarcinoma metastases. Int J Hyperthermia. 2003; 19 103-118
28 Surveillance, Epidemiology, and End Results (SEER). National Cancer Institute April/2000 http://www.seer.cancer.gov
29 Tanaka R, Kim C H, Yamada N, Saito Y. Radiofrequency hyperthermia for malignant brain tumors: preliminary results of clinical trials. Neurosurgery. 1987; 21 478-483

Correspondence to

Dr. med. Hüseyin Sahinbas

Universität Witten/Herdecke
Grönemeyer Institut

Universitätsstr. 140

44799 Bochum

eMail: sahinbas@microtherapy.de